Today: 22 May 2026
Browse Category

NYSE:ELV 21 October 2025 - 9 January 2026

UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

U.S. House committees summoned UnitedHealth and four other insurers to testify on coverage affordability Jan. 22. UnitedHealth shares rose 1.5% to $346.85 after Wolfe Research raised its price target to $400. The company reports 2025 earnings and 2026 guidance Jan. 27. Senators also accused UnitedHealth of withholding documents in a nursing home care probe.
9 January 2026
·····
UnitedHealth Group Incorporated stock rises as House summons insurer CEOs; investors eye two January dates

UnitedHealth Group Incorporated stock rises as House summons insurer CEOs; investors eye two January dates

UnitedHealth shares rose 1.3% to $346.11 after U.S. House lawmakers called major health insurer CEOs to testify on coverage affordability January 22. Senators Wyden and Warren accused UnitedHealth of withholding documents in a nursing-home probe, setting a January 28 deadline. TPG is in advanced talks to buy UnitedHealth’s Optum UK unit for up to £1.4 billion, Sky News reported.
8 January 2026
····
UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth shares rose 0.8% to $338.94 in late-morning trading Monday after Barclays raised its price target to $391 and reiterated an Overweight rating. Investors are watching ahead of Jan. 27, when UnitedHealth will report 2025 results and 2026 guidance. Scrutiny remains on medical-cost trends, operational review progress, and ongoing Justice Department investigations into Medicare Advantage billing.
5 January 2026
·····
UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth Group shares rose 1.9% to $336.40 Friday, trading 6.9 million shares and closing above key moving averages. The company will report full-year results and its 2026 outlook before the market opens Jan. 27. UnitedHealth remains under Justice Department investigation over billing practices. The stock is well below its 52-week high of $606.36.
5 January 2026
····
Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)

Elevance Health shares held near $360.52 on Dec. 12 after jumping 5.6% Thursday, breaking above their 200-day moving average. The US Senate failed overnight to extend enhanced ACA subsidies, raising the risk of higher premiums for about 24 million Americans in 2026. Congress is not expected to revisit the issue until January. ELV’s 52-week range spans $273.71 to $458.75.
12 December 2025
Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

Elevance Health (ELV) Stock: December 2025 Outlook After Q3 Earnings Beat, Legal Headwinds and New Analyst Targets

Elevance Health shares traded near $331 early December 3, about 30% below their 52-week high despite a strong Q3 earnings report. The stock is down 18% over the past year, underperforming the S&P 500. Q3 operating revenue rose 12% to $50.1 billion, with net income up nearly 18% to $1.2 billion. Shares fell 2.5% at the start of December before stabilizing.
3 December 2025
·
Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health Stock Soars on Massive Q3 Earnings Beat – What It Means for Investors

Elevance Health reported Q3 2025 adjusted earnings of $6.03 per share, beating analyst estimates by over $1. Revenue reached $50.1 billion, up 12% year-over-year and ahead of forecasts. Shares jumped as much as 7% pre-market on Oct. 21 before settling near the prior close. The company reaffirmed its full-year outlook and kept costs slightly below expectations.
21 October 2025
····
1 2

Stock Market Today

  • Q1 Earnings Review: Azenta Falls; West Pharmaceutical Leads Drug Development Services Stocks
    May 21, 2026, 9:31 PM EDT. Drug development inputs and services stocks, essential for pharmaceutical research and manufacturing, reported mixed Q1 results. Azenta (NASDAQ:AZTA), specializing in biological sample management, posted disappointing results with $144.8 million revenue, missing estimates and the weakest among peers, causing its share price to drop 23.4% to $17.65. Conversely, West Pharmaceutical Services (NYSE:WST), maker of specialized packaging and delivery devices, delivered a strong quarter with $844.9 million revenue, beating estimates by 8.4%. Overall, the sector's revenues beat consensus by 1.6%, despite an average 2.5% share price decline post-earnings. Tailwinds include growth in biologics and gene therapies, while headwinds feature pricing pressure and regulatory risks.

Latest articles

OpenAI Shares Hype Returns, Still No Ticker in Sight

OpenAI Shares Hype Returns, Still No Ticker in Sight

22 May 2026
OpenAI is preparing to confidentially file for a U.S. IPO, aiming to go public as early as September, sources told Reuters. The move follows a court win against Elon Musk, removing a key legal obstacle. Private-market share prices for OpenAI ranged from $658.94 to $732.38 this month, but no official public price exists. Ordinary investors still cannot buy OpenAI stock on public exchanges.
Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

22 May 2026
Estée Lauder and Spain’s Puig ended merger talks that would have created a $40 billion beauty group. Estée Lauder shares rose about 10% in after-hours trading, closing the regular session at $78.91. The company said it will focus on its turnaround plan and continue reviewing possible acquisitions or divestitures.
WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

22 May 2026
WhiteFiber shares jumped 22.2% to $29.55 after announcing a five-year AI compute contract worth over $160 million for a Paris-region deployment using NVIDIA GPU systems. Google Finance showed the stock rising further after hours. The project is backed by planned financing and 12 months of customer prepayments, but funding and execution remain pending. Service is expected to start in July, subject to equipment delivery and acceptance.
Go toTop